The cream formulation will now undergo further testing for stability in the coming weeks.
The company's SkinBiotix platform uses extracts of probiotic bacteria for application to the skin and SkinBio has shown in skin models that its technology can improve the skin's barrier function.
The data from the tests showed a direct correlation between the amount of SkinBiotix within the cream and the level present of a specific protein essential to the barrier function of the skin. Work on creating skin lotion and gel formulations is ongoing.
"The incorporation of our SkinBiotix technology into an effective cream formulation is a major milestone in the development of products for the cosmetic market and, subject to stability testing, allows us to create formulations for our human study later this year," said Dr Catherine O'Neill, the chief executive officer of SkinBioTherapeutics.
Shares in SkinBio opened 6.4% higher at 10.375p.